Heptalgin: new name in pain therapy.

Contributors

Glaxo Laboratories

Publication/Creation

[1949?]

Persistent URL

https://wellcomecollection.org/works/ec6r4z3z

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



- activity six times that of morphine
- twenty times that of pethidine
 - three times that of amidone



HEPTALGIN

New name in pain therapy therapy takes a step forward with the introduction of 'Heptalgin,' a compound evolved and synthesised in the Glaxo Research Laboratories.

'Heptalgin' has an analgesic activity appreciably greater than that of any of its predecessors in this field—six times that of morphine, twenty times that of pethidine, and at least three times that of amidone.

Chemically, 'Heptalgin' is 6-morpholino-4: 4-diphenylheptane-3-one hydrochloride. It is presented for clinical use in tablets containing 10 mg. for oral administration; and in ampoules containing 10 mg. in solution for intramuscular injection.

The action of 'HEPTALGIN' is

Given orally 'Heptalgin' takes effect within fifteen to thirty minutes. Parenteral administration produces even prompter relief.

'Heptalgin' abolishes pain, with little or no accompanying cortical depression. Apart from mild drowsiness following full dosage, hypnotic effects have not been noticed, and the drug has only a slight depressant influence on the respiratory centre.

In general, when given by mouth, 'Heptalgin' secures relief from pain for three to four hours. By intramuscular or subcutaneous injection, relief usually lasts for one or two hours.

HEPTALGIN

Brand Morpholinodiphenylheptanone hydrochloride

In clinical trials 'Heptalgin' has given relief from pain in cases of fibrositis, pleurisy and coronary thrombosis; in the headache of subarachnoid haemorrhage; in gall bladder and ureteric colic; in cases of inoperable malignant growth; in sinusitis, toothache and gastric ulcer. Dosage varies from one to three tablets by mouth. By injection the maximum dose is I cc.



HEPTALGIN

Brand Morpholinodiphenylheptanone hydrochloride.

Tablets: In Bottles of 25, 3/6 and 100, 10/6

Ampoules: In Boxes of 6 X I cc., 5/6

Less usual professional discount.

Glaxo Laboratories Ltd., Greenford, Middlesex.
BYRon 3434.

SC1133.

B.M.C. 0149